Changeflow GovPing Banking & Finance SEC Settles Insider Trading Action Against Rake...
Priority review Enforcement Amended Final

SEC Settles Insider Trading Action Against Rakesh Ahuja

Favicon for www.sec.gov SEC Litigation Releases
Filed
Detected
Email

Summary

The SEC filed a settled civil action against Rakesh Ahuja, a former employee of an investment advisory firm, for insider trading based on confidential clinical trial data obtained during employment. Ahuja traded on material nonpublic information on four occasions in connection with three publicly traded biopharmaceutical and biotechnology companies, generating approximately $65,000 in profits. Without admitting or denying the allegations, Ahuja consented to a permanent injunction, a two-year ban from the securities industry, and financial penalties totaling $143,097.51 including disgorgement, prejudgment interest, and a civil penalty.

Why this matters

Registered investment advisers that receive confidential information from portfolio companies as part of their due diligence process should review their information-barrier policies and personal trading pre-clearance procedures. The conduct here — using MNPI obtained through the advisory firm's due diligence workflow — is the specific pattern the SEC charged, and firms with similar research or portfolio-monitoring functions should audit whether their controls prevent employees from trading on information gathered during advisory services.

AI-drafted from the source document, validated against GovPing's analyst note standards . For the primary regulatory language, read the source document .
Published by SEC on sec.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The SEC filed a settled enforcement action alleging that Rakesh Ahuja, a former investment advisory firm employee, breached his fiduciary duty by trading on material nonpublic information received through his employer's due diligence process. The complaint describes how Ahuja used confidential clinical trial data from biopharmaceutical companies to time trades through a relative's brokerage account, resulting in approximately $65,000 of illicit profits across four trading occasions involving three companies.

Investment advisory firms and their employees should note the enforcement focus on misuse of confidential due diligence information. Registered investment advisers should review their information-barrier and personal trading compliance policies to ensure that employees do not use MNPI obtained during advisory services. The two-year industry ban and the civil penalty equal to the profit amount signal that the SEC will seek significant remedies beyond disgorgement in insider trading cases.

Penalties

Disgorgement of $65,404.25, prejudgment interest of $12,289.01, and civil penalty of $65,404.25 (total $143,097.51)

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

More in this Section

Rakesh Ahuja

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 26533 / April 21, 2026

Securities and Exchange Commission v. Rakesh Ahuja, Civil Case No. 26-cv-03213 (S.D.N.Y. filed April 20, 2026)

SEC Files Settled Action as to Former Investment Advisory Firm Employee Charged with Insider Trading

On April 20, 2026, the Securities and Exchange Commission filed a settled action as to Rakesh Ahuja, a former employee of an investment advisory firm, for allegedly insider trading based on confidential information he obtained during his employment.

According to the SEC’s complaint, filed in the United States District Court for the Southern District of New York, Ahuja worked for an investment advisory firm that provided investment advisory services to two pooled investment funds that specialized in making investments in biopharmaceutical and biotechnology companies. The SEC alleges that the advisory firm provided Anuja with material nonpublic information, including confidential clinical trial data, from these companies as part of its due diligence process. The SEC further alleges that on multiple occasions, Ahuja breached his duty to the advisory firm by causing a brokerage account in the name of one of his close relatives to trade based on material nonpublic information in advance of announcements by companies he was researching for the advisory firm. Ahuja allegedly engaged in this conduct in connection with three publicly traded companies on a total of four occasions. According to the complaint, Ahuja’s unlawful trades resulted in profits of approximately $65,000.

Without admitting or denying the allegations, Ahuja consented to the entry of a final judgment, subject to court approval, in which he agreed to be permanently enjoined from violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder; enjoined from acting as or being associated with an investment adviser, broker, or dealer for a period of two years; and to pay disgorgement of $65,404.25, prejudgment interest of $12,289.01, and a civil penalty of $65,404.25.

The SEC’s investigation was conducted by Frank Goldman, Patrick McCluskey, and Danielle R. Voorhees of the Division of Enforcement’s Market Abuse Unit, under the supervision of Joseph G. Sansone, Chief of the Market Abuse Unit, with the assistance of trial counsel Sharan Lieberman under the supervision of Gregory A. Kasper of the SEC’s Denver Regional Office. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.

Resources

Named provisions

Section 10(b) of the Securities Exchange Act of 1934 Rule 10b-5

Get daily alerts for SEC Litigation Releases

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from SEC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
SEC
Filed
April 21st, 2026
Instrument
Enforcement
Branch
Executive
Joint with
FINRA
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
Litigation Release No. 26533
Docket
26-cv-03213

Who this affects

Applies to
Broker-dealers Investment advisers Financial advisers
Industry sector
5231 Securities & Investments
Activity scope
Insider trading enforcement Investment advisory services Securities fraud
Geographic scope
United States US

Taxonomy

Primary area
Securities
Operational domain
Legal
Compliance frameworks
SOX
Topics
Securities Anti-Money Laundering

Get alerts for this source

We'll email you when SEC Litigation Releases publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!